Everesting: cycling the elevation of the tallest mountain on Earth.

Eur J Appl Physiol

Integrative Locomotion Laboratory, Department of Kinesiology, University of Massachusetts, Amherst, USA.

Published: December 2022

Purpose: With few cycling races on the calendar in 2020 due to COVID-19, Everesting became a popular challenge: you select one hill and cycle up and down it until you reach the accumulated elevation of Mt. Everest (8,848 m or 29,029ft). With an almost infinite number of different hills across the world, the question arises what the optimal hill for Everesting would be. Here, we address the biomechanics and energetics of up- and downhill cycling to determine the characteristics of this optimal hill.

Methods: During uphill cycling, the mechanical power output equals the power necessary to overcome air resistance, rolling resistance, and work against gravity, and for a fast Everesting time, one should maximize this latter term. To determine the optimal section length (i.e., number of repetitions), we applied the critical power concept and assumed that the U-turn associated with an additional repetition comes with a 6 s time penalty.

Results: To use most mechanical power to overcoming gravity, slopes of at least 12% are most suitable, especially since gross efficiency seems only minimally diminished on steeper slopes. Next, we found 24 repetitions to be optimal, yet this number slightly depends on the assumptions made. Finally, we discuss other factors (fueling, altitude, fatigue) not incorporated in the model but also affecting Everesting performances.

Conclusion: For a fast Everesting time, our model suggests to select a hill climb which preferably starts at (or close to) sea level, with a slope of 12-20% and length of 2-3 km.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444120PMC
http://dx.doi.org/10.1007/s00421-022-05032-zDOI Listing

Publication Analysis

Top Keywords

select hill
8
mechanical power
8
fast everesting
8
everesting time
8
everesting
6
everesting cycling
4
cycling elevation
4
elevation tallest
4
tallest mountain
4
mountain earth
4

Similar Publications

Background Context: There are a number of risk factors- from biological, psychological, and social domains- for non-specific chronic low back pain (cLBP). Many cLBP treatments target risk factors on the assumption that the targeted factor is not just associated with cLBP but is also a cause (i.e, a causal risk factor).

View Article and Find Full Text PDF

Background: Certain micronutrient levels have been associated with the risk of developing TB disease. We explored the possible association of selected at-risk micronutrient levels with the development of Mycobacterium tuberculosis (M.tb) infection.

View Article and Find Full Text PDF

Pros and Cons of Inpatient SGLT2i Use for Hyperglycemia and Heart Failure.

J Endocr Soc

January 2025

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Division of Endocrinology, Diabetes and Metabolism, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY 11040, USA.

Sodium-glucose cotransporter 2 inhibitors (SGLT2is), originally approved by the US Food and Drug Administration for glycemic control in type 2 diabetes mellitus (DM2), have shown substantial cardiovascular and renal benefits, leading to their expanded use in managing heart failure (HF) and chronic kidney disease in the outpatient setting. Despite these benefits, their use for inpatient hyperglycemia management is not universally endorsed due to safety concerns and inadequate data. However, emerging evidence suggests potential advantages of initiating SGLT2i treatment for patients during hospitalization in the setting of HF.

View Article and Find Full Text PDF

Many human diseases result from a complex interplay of behavioral, clinical, and molecular factors. Integrating low-dimensional behavioral and clinical features with high-dimensional molecular profiles can significantly improve disease outcome prediction and diagnosis. However, while some biomarkers are crucial, many lack informative value.

View Article and Find Full Text PDF

Histone mutations (H3 K27M, H3 G34R/V) are molecular features defining subtypes of paediatric-type diffuse high-grade gliomas (HGG) (diffuse midline glioma (DMG), H3 K27-altered, diffuse hemispheric glioma (DHG), H3 G34-mutant). The WHO classification recognises in exceptional cases, these mutations co-occur. We report one such case of a 2-year-old female presenting with neurological symptoms; MRI imaging identified a brainstem lesion which was biopsied.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!